These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27123592)

  • 1. Rational Structure-Based Rescaffolding Approach to De Novo Design of Interleukin 10 (IL-10) Receptor-1 Mimetics.
    Ruiz-Gómez G; Hawkins JC; Philipp J; Künze G; Wodtke R; Löser R; Fahmy K; Pisabarro MT
    PLoS One; 2016; 11(4):e0154046. PubMed ID: 27123592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limiting Assumptions in the Design of Peptidomimetics.
    Marshall GR; Ballante F
    Drug Dev Res; 2017 Sep; 78(6):245-267. PubMed ID: 28875546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural analysis of cytokines comprising the IL-10 family.
    Zdanov A
    Cytokine Growth Factor Rev; 2010 Oct; 21(5):325-30. PubMed ID: 20846897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based inhibition of protein-protein interactions.
    Watkins AM; Arora PS
    Eur J Med Chem; 2015 Apr; 94():480-8. PubMed ID: 25253637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exome sequencing identifies novel compound heterozygous mutations of IL-10 receptor 1 in neonatal-onset Crohn's disease.
    Mao H; Yang W; Lee PP; Ho MH; Yang J; Zeng S; Chong CY; Lee TL; Tu W; Lau YL
    Genes Immun; 2012 Jul; 13(5):437-42. PubMed ID: 22476154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclopropane-Based Peptidomimetics Mimicking Wide-Ranging Secondary Structures of Peptides: Conformational Analysis and Their Use in Rational Ligand Optimization.
    Mizuno A; Kameda T; Kuwahara T; Endoh H; Ito Y; Yamada S; Hasegawa K; Yamano A; Watanabe M; Arisawa M; Shuto S
    Chemistry; 2017 Mar; 23(13):3159-3168. PubMed ID: 28000361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex.
    Yoon SI; Logsdon NJ; Sheikh F; Donnelly RP; Walter MR
    J Biol Chem; 2006 Nov; 281(46):35088-96. PubMed ID: 16982608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10.
    Saxton RA; Tsutsumi N; Su LL; Abhiraman GC; Mohan K; Henneberg LT; Aduri NG; Gati C; Garcia KC
    Science; 2021 Mar; 371(6535):. PubMed ID: 33737461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic antibody mimics for the inhibition of protein-ligand interactions.
    Haußner C; Lach J; Eichler J
    Curr Opin Chem Biol; 2017 Oct; 40():72-77. PubMed ID: 28735229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis of the Pekin duck interleukin-10 receptor 1.
    Yao Q; Fischer KP; Tyrrell DL; Gutfreund KS
    Int J Immunogenet; 2012 Feb; 39(1):55-67. PubMed ID: 22098679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New mimetic peptides inhibitors of Αβ aggregation. Molecular guidance for rational drug design.
    Barrera Guisasola EE; Andujar SA; Hubin E; Broersen K; Kraan IM; Méndez L; Delpiccolo CM; Masman MF; Rodríguez AM; Enriz RD
    Eur J Med Chem; 2015 May; 95():136-52. PubMed ID: 25805447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the design of insulin and relaxin/insulin-like peptide mimetics.
    Hossain MA; Bathgate RAD
    Bioorg Med Chem; 2018 Jun; 26(10):2827-2841. PubMed ID: 28988628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural network of Interleukin-10 and its implications in inflammation and cancer.
    Acuner-Ozbabacan ES; Engin BH; Guven-Maiorov E; Kuzu G; Muratcioglu S; Baspinar A; Chen Z; Van Waes C; Gursoy A; Keskin O; Nussinov R
    BMC Genomics; 2014; 15 Suppl 4(Suppl 4):S2. PubMed ID: 25056661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Structural Basis for Class II Cytokine Receptor Recognition by JAK1.
    Ferrao R; Wallweber HJ; Ho H; Tam C; Franke Y; Quinn J; Lupardus PJ
    Structure; 2016 Jun; 24(6):897-905. PubMed ID: 27133025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining scaffold geometries for interacting with proteins: geometrical classification of secondary structure linking regions.
    Tran TT; Kulis C; Long SM; Bryant D; Adams P; Smythe ML
    J Comput Aided Mol Des; 2010 Nov; 24(11):917-34. PubMed ID: 20862601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping of the interleukin-10/interleukin-10 receptor combining site.
    Reineke U; Sabat R; Volk HD; Schneider-Mergener J
    Protein Sci; 1998 Apr; 7(4):951-60. PubMed ID: 9568901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes.
    Pelay-Gimeno M; Glas A; Koch O; Grossmann TN
    Angew Chem Int Ed Engl; 2015 Jul; 54(31):8896-927. PubMed ID: 26119925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IVGA3D: De novo ligand design using a variable sized tree representation.
    Bandyopadhyay S; Sengupta S
    Protein Pept Lett; 2010 Dec; 17(12):1495-516. PubMed ID: 20518735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of a GCN4-derived mimetic of interleukin-4.
    Domingues H; Cregut D; Sebald W; Oschkinat H; Serrano L
    Nat Struct Biol; 1999 Jul; 6(7):652-6. PubMed ID: 10404222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a tightly bound water molecule on scaffold diversity in the computer-aided de novo ligand design of CDK2 inhibitors.
    García-Sosa AT; Mancera RL
    J Mol Model; 2006 Mar; 12(4):422-31. PubMed ID: 16374623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.